In Episode 4 Emily speaks with Jay Bhattacharya. Jay is a Professor of Medicine at Stanford University, who focuses much of his research on the economics of health care. He was a voice of reason in the early days of the COVID-19 pandemic, first questioning the severity of the virus, then following up with his Santa Clara study, revealing the virus’s existing prevalence, drastically decreasing the perceived death rate from the disease.
Bhattacharya holds both an MD from Stanford and a Ph.D. in economics, making him uniquely adept in understanding trade-offs in healthcare. Some of his early works focused on the healthcare costs related to obesity, revealing that obese workers bear the costs of their higher healthcare usage through lower wages in jobs with health insurance.
During the COVID-19 pandemic Jay opposed lockdowns and other public health measures, which sparked significant controversy, including personal attacks and institutional pressure, such a “fact-finding” investigation by Stanford, his employer. He later co-authored the Great Barrington Declaration, which advocated for focused protection of vulnerable populations rather than blanket lockdowns. The Declaration faced swift backlash from public health authorities like Anthony Fauci and Francis Collins, as well as censorship by tech companies.
Through it all, Bhattacharya holds true to his belief in the importance of critical thinking, intellectual honesty, and the willingness to challenge authority, particularly in times of crisis. He’s found freedom in standing by his principles despite professional and personal attacks.
LISTEN AS A PODCAST
The art and science of changing our collective conversation. This critical thinking project highlights the people who are smart enough to see the problem AND brave enough to expose it. The show pays homage to those who dare to challenge conventional wisdom.
Support the Broken Science Initiative.
Subscribe today →
One Comment
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
This was a great interview! It was good to take a look back at scientific misconduct of 2020 to hopefully prevent this from happening again. Or at least so I don’t fall for taking experimental drugs and adopt unscientific measures.
Thank you both